{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:57Z","timestamp":1790957577986,"version":"4.1.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamaneurol.2019.0079","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T04:31:25Z","timestamp":1549600285000},"page":"526","source":"Crossref","is-referenced-by-count":100,"title":["Pioglitazone Therapy in Patients With Stroke and Prediabetes"],"prefix":"10.1001","volume":"76","author":[{"given":"J. David","family":"Spence","sequence":"first","affiliation":[{"name":"Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Viscoli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dearborn-Tomazos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Ford","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, University of Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gorman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Maine Medical Center, Portland, Maine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Furie","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Lovejoy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter N.","family":"Kernan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the IRIS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"noi190003r1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/01.STR.25.5.951","article-title":"Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program.","volume":"25","author":"Burchfiel","year":"1994","journal-title":"Stroke"},{"issue":"7","key":"noi190003r2","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/dc06-2363","article-title":"Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses\u2019 Health Study.","volume":"30","author":"Janghorbani","year":"2007","journal-title":"Diabetes Care"},{"issue":"9","key":"noi190003r3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1212\/01.WNL.0000063318.66140.A3","article-title":"Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke.","volume":"60","author":"Kernan","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"noi190003r4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1172\/JCI67166","article-title":"Insulin resistance in the vasculature.","volume":"123","author":"Mather","year":"2013","journal-title":"J Clin Invest"},{"issue":"7","key":"noi190003r5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1172\/JCI29024","article-title":"Insulin resistance and atherosclerosis.","volume":"116","author":"Semenkovich","year":"2006","journal-title":"J Clin Invest"},{"issue":"6","key":"noi190003r6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1212\/WNL.59.6.809","article-title":"Insulin resistance and risk for stroke.","volume":"59","author":"Kernan","year":"2002","journal-title":"Neurology"},{"issue":"7","key":"noi190003r7","doi-asserted-by":"publisher","first-page":"e102190","DOI":"10.1371\/journal.pone.0102190","article-title":"Pioglitazone treatment reduces adipose tissue inflammation through reduction of mast cell and macrophage number and by improving vascularity.","volume":"9","author":"Spencer","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"noi190003r8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cdr.2015.33.issue-3","article-title":"Plaque thrombosis is reduced by attenuating plaque inflammation with pioglitazone and is evaluated by fluorodeoxyglucose positron emission tomography.","volume":"33","author":"Zhang","year":"2015","journal-title":"Cardiovasc Ther"},{"issue":"11","key":"noi190003r9","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones.","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"noi190003r10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs.","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"issue":"3","key":"noi190003r11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"issue":"14","key":"noi190003r12","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack.","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"noi190003r13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","article-title":"Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis.","volume":"48","author":"Lee","year":"2017","journal-title":"Stroke"},{"key":"noi190003r14","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc16-S005","article-title":"2: Classification and diagnosis of diabetes.","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"noi190003r15","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcjd.2017.10.003","article-title":"Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome.","volume":"42","author":"Punthakee","year":"2018","journal-title":"Can J Diabetes"},{"issue":"7","key":"noi190003r16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00125-013-2902-4","article-title":"Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis.","volume":"56","author":"Morris","year":"2013","journal-title":"Diabetologia"},{"issue":"7557","key":"noi190003r17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.38875.675486.55","article-title":"A meta-analysis of the association between adherence to drug therapy and mortality.","volume":"333","author":"Simpson","year":"2006","journal-title":"BMJ"},{"issue":"20","key":"noi190003r18","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.116.024863","article-title":"Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus.","volume":"135","author":"Young","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"noi190003r19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.117.030458","article-title":"Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke).","volume":"137","author":"Yaghi","year":"2018","journal-title":"Circulation"},{"key":"noi190003r20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"noi190003r21","doi-asserted-by":"publisher","first-page":"e000697","DOI":"10.1161\/JAHA.113.000697","article-title":"Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.","volume":"3","author":"Armstrong","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"noi190003r22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes.","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"noi190003r24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1159\/000360810","article-title":"Prediabetes in patients with stroke or transient ischemic attack: prevalence, risk and clinical management.","volume":"37","author":"Fonville","year":"2014","journal-title":"Cerebrovasc Dis"},{"issue":"12","key":"noi190003r25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2337\/dc18-1132","article-title":"Prediabetes is associated with structural brain abnormalities: the Maastricht Study.","volume":"41","author":"van Agtmaal","year":"2018","journal-title":"Diabetes Care"},{"issue":"14","key":"noi190003r26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials.","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"noi190003r27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/0009-9236(95)90260-0","article-title":"Intention-to-treat analysis and the goals of clinical trials.","volume":"57","author":"Sheiner","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"noi190003r28","doi-asserted-by":"publisher","first-page":"628628","DOI":"10.1155\/2013\/628628","article-title":"Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms.","volume":"2013","author":"Beltowski","year":"2013","journal-title":"PPAR Res"},{"issue":"5","key":"noi190003r29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.2040-1124.2010.00046.x","article-title":"Relationship between urinary sodium excretion and pioglitazone-induced edema.","volume":"1","author":"Nakamura","year":"2010","journal-title":"J Diabetes Investig"},{"key":"noi190003r30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2016.11.126","article-title":"The low dose (7.5mg\/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure.","volume":"227","author":"Adachi","year":"2017","journal-title":"Int J Cardiol"},{"issue":"9","key":"noi190003r31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/ajh\/hpx066","article-title":"Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa.","volume":"30","author":"Akintunde","year":"2017","journal-title":"Am J Hypertens"},{"issue":"2","key":"noi190003r32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.118.11064","article-title":"Hypertension in blacks: individualized therapy based on renin\/aldosterone phenotyping.","volume":"72","author":"Spence","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"noi190003r33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2215\/CJN.06330612","article-title":"Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.","volume":"8","author":"Viswanathan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"noi190003r23","author":"Inzucchi"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaneurology\/article-pdf\/76\/5\/526\/17579751\/jamaneurology_spence_2019_oi_190003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T15:02:31Z","timestamp":1557759751000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2019.0079"}},"subtitle":["A Post Hoc Analysis of the IRIS Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2019.0079","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}